Pancreatic Cancer Early Detection Consortium
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorArbor Research Collaborative for Health
About this trial
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Eligibility criteria
Qualifiers
2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
Disqualifiers
Individuals not meeting the criteria above.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
20,000 Participants
are grouped into 10 trial groups10
Trial groupsSee each trial group below.
Sponsors and collaborators
Source ClinicalTrials.gov